Tech Company Financing Transactions
Vinci Pharmaceuticals Funding Round
Vinci Pharmaceuticals closed a $8 million Series A investment round on 10/8/2026. Investors included Dynagrow Capital and MintPharma Capital.
Transaction Overview
Company Name
Announced On
10/8/2026
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
Dynagrow Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support GMP manufacturing, testing and release activities of the Epiplant VCI-002 product, and the Phase 1/2a study in 2027.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12 Washington Avenue
Avon-by-the-Sea, NJ 07717
USA
Avon-by-the-Sea, NJ 07717
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Vinci Pharmaceuticals is a specialty ophthalmic pharmaceutical company motivated to disrupt the treatment of retinal diseases with novel, next generation platform technologies. Our proprietary solution is EPIPLANT�, a transformative platform technology that provides safe, effective and needle free drug delivery to the retina.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philip Gioia
Browse more venture capital transactions:
Prev: 10/8/2026: Fortastra venture capital transaction
Next: 10/8/2026: Thrixel venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs